Full-Time
Confirmed live in the last 24 hours
Develops gene editing technology for genetic medicine
Entry, Junior, Mid
Cambridge, MA, USA
Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments. Tessera generates revenue through partnerships, licensing agreements, and the potential sale of its technology. With significant funding secured, Tessera aims to advance its platform and fulfill its goal of curing diseases by rewriting genetic code.
Company Stage
Series C
Total Funding
$517.2M
Headquarters
Cambridge, Massachusetts
Founded
2018
Help us improve and share your feedback! Did you find this helpful?